DA-1726_Dosage, benefits & legal status
Also known as DA1726, DA 1726
A 68% liver-fat result built on four placebo patients whose liver fat went up.
What is DA-1726?
Plain language first. The technical label stays, but it never stands alone.Overview
This is an early-stage weekly injection that activates two hormone receptors at once, GLP-1 for appetite and glucagon for energy burn and liver fat. In November 2026 its developer announced a 68% reduction in liver fat and 13.5% weight loss after 16 weeks, and those numbers traveled fast. They are worth understanding before repeating. The liver fat result compares 12 people on the drug against 4 on placebo. The people on the drug started with an average liver fat of 5.2%, barely above the 5% line that defines a fatty liver at all, and the four on placebo got worse, with their liver fat rising 40% over the study. A placebo-adjusted percentage gets larger both when the drug arm improves and when the placebo arm deteriorates, so a four-person placebo group moving in the wrong direction does a lot of the work in that 68%. The weight result is simpler: average weight fell from 98.6 kg to 86.4 kg, a real 12.19 kg. None of this is a reason to dismiss the drug. It is a reason not to compare a nineteen-person phase 1 interim analysis with the large trials behind approved drugs.
DA-1726 is an oxyntomodulin-derived dual agonist of the GLP-1 and glucagon receptors, engineered to a roughly 3-to-1 GLP-1 to glucagon potency ratio, given under the skin once weekly and developed by MetaVia, an affiliate of Dong-A ST. It is in a first-in-human phase 1 trial whose registered primary endpoint is adverse events, not efficacy. An interim analysis of one part of that trial, presented in November 2026, reported a 68% placebo-adjusted reduction in liver fat and a 13.5% placebo-adjusted reduction in body weight at day 109 in otherwise healthy adults with obesity. The weight figure rests on 15 treated participants and 4 on placebo; the liver fat figure on 12 and 4. Approved nowhere, and no phase 2 trial has started.
What it's used for
Under study in adults with obesity in a phase 1 trial. The developer has said it will expand into metabolic and alcohol-associated liver disease, with a 48-week phase 2 planned for the second half of 2027. There is no approved use.
How does DA-1726 work?
What it does in the body, and where.Oxyntomodulin is a natural gut hormone that hits two receptors. GLP-1 curbs appetite. Glucagon raises energy expenditure and pushes the liver to burn fat. Analogs of it try to balance the two.
- 01The GLP-1 side reduces appetiteIt also slows gastric emptying, the mechanism behind weight loss in this whole drug class.
- 02The glucagon side acts on the liverRaised energy expenditure and a direct hepatic effect, the stated rationale for targeting liver fat.
- 03The ratio between them is the design choiceThis molecule is tuned to roughly 3-to-1 GLP-1 to glucagon potency, the dial every developer in this class sets differently.
- 04Where it goes is the claim being testedPreclinical work reported the compound concentrating in fat tissue and liver, and the interim MRI result is offered as clinical support for that.
What else is it used for?
Each group carries its own evidence level.Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
Part 3B interim, and what the numbers rest on
Early research- human-earlyDay 109 interim analysis presented as an oral presentation at a liver disease symposium in Denver on November 4, 2026, and announced the following day: 68% placebo-adjusted liver fat reduction, 13.5% placebo-adjusted body weight reduction, 0.24 percentage point placebo-adjusted HbA1c reduction.
- human-earlyGroup sizes: 15 participants treated with DA-1726 and 4 on placebo in the part reported; the MRI substudy behind the liver fat figure included 12 treated and 4 placebo participants.
- No dataMean baseline liver fat by MRI-PDFF was 5.2% in treated participants and 8.0% in the placebo group, and the placebo group's liver fat rose 40.4% from its own baseline. Both facts inflate a placebo-adjusted percentage, and neither appears in most reports of the 68%.
- human-earlyWithin-group results: 10 of 12 treated participants reached at least a 30% relative liver fat reduction against 0 of 4 on placebo; all five treated participants with baseline steatosis finished under 5% MRI-PDFF; the highest-baseline participant went from 12.8% to 4.6%.
- human-earlyAbsolute weight change: 98.6 kg to 86.4 kg, a 12.19 kg loss, with reductions in visceral and subcutaneous adipose tissue and lean tissue and muscle volume described as relatively preserved. No participant discontinued for a gastrointestinal adverse event.
What the trial was registered to measure
Investigational- RegulatoryThe primary outcome of NCT06252220 is the number of participants with treatment-related adverse events, graded by CTCAE, from randomization through up to 24 weeks post-dose. Liver fat and body weight are not the registered primary endpoint, and the MRI substudy does not appear in the registered primary outcome at all.
- RegulatoryEligibility was adults aged 18 to 65 with a body mass index of 30 to 45, otherwise healthy or with stable obesity-related conditions, and explicitly not diabetic: a history of diabetes, a fasting glucose of 120 mg/dL or more, or HbA1c of 6.5% or more were exclusions.
- No dataThe registry record names NeuroBo Pharmaceuticals as sponsor, the company's former name, and was last updated April 9, 2026. It lists Part 3 as a titration part using one-step or two-step titration and never uses the designation Part 3B, so the reported analysis cannot be matched to a registered arm from public records.
What comes next, and the reception
Investigational- RegulatoryThe developer plans full phase 1 results in the first quarter of 2027 and a 48-week phase 2 trial in metabolic and alcohol-associated liver disease in the second half of 2027. Alcohol-associated liver disease has no approved drug treatment, the strategic argument for the pivot.
- ReviewTrade coverage of the same announcement was measured rather than enthusiastic, with one outlet headlining that the phase 1 failed to impress investors. A 68% number and a flat share price in the same week is usually a sign the denominator was read.
The 68% figure, repeated without its denominator. Twelve people on the drug, four on placebo, in the part of a phase 1 study whose registered primary endpoint is adverse events rather than efficacy. The second thing commonly dropped is the baseline: average liver fat in the treated group was 5.2%, just over the threshold for fatty liver, so this was not a study of people with liver disease. The third is the direction of the placebo arm, whose liver fat rose 40.4%. The 13.5% weight figure is also placebo-adjusted; the absolute fall was 12.19 kg from a 98.6 kg mean, about 12.4%.
The published record
0
Papers about DA-1726 · this compound only
Searched: DA-1726, DA1726.
Left out: oxyntomodulin (the PARENT HORMONE, which has its own card on this site. A query on the family term returns the natural peptide's physiology literature and four other cards); efinopegdutide (a GLP-1/glucagon dual agonist on this site with its own liver fat result in MASH. The single most likely source of borrowed numbers, because it is the same mechanism aimed at the same organ); mazdutide (another GLP-1/glucagon dual agonist on this site, with Chinese phase 3 data. Same class, different molecule, far more advanced); cotadutide (an earlier GLP-1/glucagon dual agonist with published liver fat data, discontinued); survodutide (a GLP-1/glucagon dual agonist on this site in phase 3 for MASH, where this drug is in phase 1. Opposite ends of the same race); DA-1241 (the developer's OTHER metabolic candidate, a GPR119 agonist in MASH. Same company, same disease area, different mechanism, no card here); MetaVia (the developer, formerly NeuroBo Pharmaceuticals, whose literature spans both names and both programs); NeuroBo Pharmaceuticals (the former name, STILL listed as sponsor in the trial registry. Searching either name alone misses records under the other); Dong-A ST (the Korean parent, with a broad unrelated portfolio); MRI-PDFF (the measurement method, used across the entire MASH literature); MetALD (the planned phase 2 indication, a recently defined term with a growing literature not about this drug); alcohol-associated liver disease (the other planned indication, a large hepatology literature).
Europe PMC was searched on November 12, 2026 for these terms and returned nothing.
Counted from Europe PMC indexing, not read by a person.
At a glance
Four things to know about DA-1726
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
Varies
Half-life
Long enough for weekly dosing; no published figure
How much, and do you cycle it?
The range, and whether you take breaks.Not published; the trial uses ascending doses and titration, once weekly. Weekly inside the trial, 16 weeks to the reported interim point Trial dose
The reported analysis is at day 109, roughly 16 weeks of once-weekly dosing. The planned phase 2 in liver disease is described as 48 weeks.
Long enough for weekly dosing; no published figureNo figure
No half-life figure has been published. Pharmacokinetics are among the stated objectives of the phase 1 trial and no results have been released.
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
How do you store it?
Before mixing, and after.Nothing to store: it is not sold anywhere.
DA-1726 has never been marketed, so there is no vial, pen or bottle to keep at home. Supplies for a trial are made, stored and dispensed by the sponsor and the trial pharmacy under conditions set in the protocol. Anything offered for sale under this name did not come from that supply chain.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- Any expectation of access: this is a phase 1 compound, approved nowhere
- Reading the 68% liver fat figure as comparable to results from liver disease trials, since these participants were otherwise healthy adults with obesity and an average liver fat of 5.2%
- Comparing the 13.5% figure with approved weight-loss drugs, whose numbers come from trials hundreds of times larger
Stop and get help
- Not applicable outside the trial, where the protocol and the investigator govern
- Rapid heart rate, or symptoms of high blood sugar, would be the signals to report promptly in a trial of a glucagon receptor agonist
Common effects
- Not characterized in public. The interim release reports efficacy measures and one negative statement about gastrointestinal discontinuations
- Reductions in visceral and subcutaneous fat, with lean tissue and muscle volume described as relatively preserved
- A small fall in HbA1c in participants who were not diabetic, from 5.79% to 5.33%, movement within the normal range
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is DA-1726 approved?
And where the numbers on this page come from.No. DA-1726 is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteUnder the skin, once weekly, inside a trial
- Checked11 November 2026
- DoseNo dose has been established in people.
- Vial sizeFrom what vendors typically list; not a recommendation.
- SourcesClinicalTrials.gov phase 1 record NCT06252220 (DA-1726-1001)MetaVia announcement of Part 3B interim data, November 5, 2026Trade coverage of the Part 3B interim data and the planned liver disease programKorea Biomedical Review report of the interim results, including the geometric mean ratio basisSecondary report carrying the baseline MRI-PDFF values and the placebo arm's 40.4% increase
What has happened recently
Approved in no country. The phase 1 trial is NCT06252220, run as study DA-1726-1001, a first-in-human single and multiple ascending dose study with a titration part, 139 participants estimated, still listed as recruiting, started March 25, 2024 with primary completion estimated November 9, 2026. Two gaps between the registry and the announcements are worth noting. The registry still names NeuroBo Pharmaceuticals as sponsor, the company's former name, and was last updated April 9, 2026. The registry describes Part 3 as a titration part using one-step or two-step titration and does not use the label Part 3B that the announcements are built on, so the reader cannot match the reported analysis to a registered arm. Full phase 1 results are promised for the first quarter of 2027.
You can compare this against the whole library, or read how to check a seller.
What else is like DA-1726?
Others in GLP-1 agonists, side by side.If you're weighing DA-1726, it's worth reading Danuglipron, Dulaglutide (Trulicity), and Ecnoglutide in the same class.
A 68% liver-fat result built on four placebo patients whose liver fat went up.
- Dose
- Not published; the trial uses ascending doses and titration
- How often
- Once weekly
An experimental weight-loss pill whose development was stopped over a liver-injury signal.
- Dose
- 40 up to 200 mg per dose
- How often
- Daily
A weekly GLP-1 shot for diabetes, with far less weight loss than the famous ones.
- Dose
- 0.75 up to 4.5 mg per week (start low, increase slowly)
- How often
- Weekly
A GLP-1 approved in China and licensed to Pfizer, and not approved in the US.
- Dose
- 1.2 to 2.4 mg
- How often
- Once weekly
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- ClinicalTrials.gov phase 1 record NCT06252220 (DA-1726-1001)
- MetaVia announcement of Part 3B interim data, November 5, 2026
- Trade coverage of the Part 3B interim data and the planned liver disease program
- Korea Biomedical Review report of the interim results, including the geometric mean ratio basis
- Secondary report carrying the baseline MRI-PDFF values and the placebo arm's 40.4% increase